Stuart Milne and Kevin Gordon will join the company as CTO and Chief Data & Operating Officer respectively
Ori Biotech, a CGT manufacturing technologies specialist, has made several appointments to its senior leadership team. This includes appointing Kevin Gordon as Chief Data and Operating Officer (CDOO) and Stuart Milne as CTO. The company is also expanding its leadership team with additional appointments.
In his role, Gordon will lead the development of the company’s cloud data analytics platform, accelerating its progress in digital, cloud-based cell and gene therapy manufacturing technology platforms. As CTO, Milne will be responsible for the hardware, software and consumable elements of the company’s full-stack manufacturing platform. The platform is designed to enable higher throughput and higher quality manufacturing for cell and gene therapies at a more affordable cost.
Gordon was previously VP of IT at Tmunity Therapeutics. His work will help standardise the approach to digital platforms and electronic manufacturing systems.
“The cell and gene therapy industry has advanced to where data platforms and electronic manufacturing systems are becoming critical components of process discovery and commercialisation of these therapies. The industry has simply outgrown the possibility of relying on paper batch records,” said Kevin Gordon, incoming CDOO, Ori Biotech.
As the company’s incoming CTO, Milne brings experience launching technical products into the CGT sector including experience in the management and development of Asymptote.
“In cell and gene therapy, clinical development has outpaced the ability to rapidly deliver therapies to patients at scale. Manufacturing remains one of the biggest challenges blocking therapeutic delivery,” said Milne, incoming CTO, Ori Biotech. “I believe Ori’s platform will revolutionise process discovery, translation and commercialization in cell and gene therapy.”
In addition, the company has expanded the leadership of its technical and scientific teams with a number of additional appointments. Courtney LeBlon has joined as Technical Director, NA after previously leading MSAT at Minaris Regenerative Medicine. Ori has also appointed Stephen Shapka as Lead Automation Engineer, Enas Hassan as Lead Scientist and Elena Chikunova as Process Development Scientist, who collectively bring a wealth of experience from prior roles at the Cell and Gene Therapy Catapult.